Inclusion Criteria:

- Patients must have histologically confirmed solid malignancy that is metastatic or
unresectable and for which no standard curative therapy exists; patients with
lymphoma are excluded

- ECOG performance status 0, 1, or 2 (Karnofsky >= 60%)

- Life expectancy of greater than 3 months

- Leukocytes >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelets >= 100,000/mm^3

- Total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation, and for three months after discontinuation of
treatment; should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

- Ability to understand and the willingness to sign a written informed consent document

- Patients will need to have a central line or nurse-placed PICC line in place prior to
treatment on the protocol

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients may not be receiving any other investigational agents

- Patients with known brain metastases will be excluded from this clinical trial

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to G3139 or other agents used in study, unless approved by investigator

- No pre-existing grade >= 2 neuropathy

- No personal history of a bleeding diathesis given potential significant antiplatelet
effects of therapy

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with G3139

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study